Each relationship is unique, but generally the alliances include a joint steering committee that meets regularly, dedicated project managers on both sides, a contractual framework that results in no contract or budget negotiations for 3-5 years and substantial financial and resource commitments.
Additionally, some of the alliances may contain a risk-sharing component.
The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system’s potential to fight cancer.
The alliance pairs MD Anderson’s preclinical and clinical teams with Adaptimmune’s scientists and proprietary SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell technology platform, which enables Adaptimmune to identify targets expressed on solid and hematologic cancers and to develop affinity enhanced T-cell receptors (TCRs) with optimal potency and specificity against them.
A Phase I/II clinical trial collaboration evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-602 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Exclusive strategic clinical development and commercialization collaboration to evaluate Affimed’s TandAb technology in combination with MD Anderson’s natural killer cell (NK) expertise..
The five-year collaboration aims to accelerate clinical development of select novel apoptosis-targeted and tyrosine kinase inhibitor product candidates in hematological indications.
Agreement to develop a new treatment for patients with acute myeloid leukemia.
Studies with AstraZeneca target gynecologic cancers.
Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments based on patient or tumor characteristics for which current therapies have not shown satisfactory clinical efficacy.
Boehringer Ingelheim and MD Anderson announced a new multiyear partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers.
Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration.
MD Anderson and Cellectis announce CAR T-cell preclinical and clinical strategic alliance.
MD Anderson Cancer Center and Daiichi Sankyo Company, Limited announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML).
MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., announced a strategic collaboration to bring Dragonfly’s TriNKET™ (tri-specific natural killer cell engager therapy) immunotherapy drug candidates to patients in clinical trials beginning in 2019.
MD Anderson Cancer Center and EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced a three-year strategic collaboration, with the aim of more quickly advancing the development of investigational cancer therapies in four cancers – breast, colorectal, glioblastoma and leukemia.
Forty Seven and MD Anderson entered into a collaboration to design immunotherapy trials and monitor immune function in connection with the company’s studies.
A strategic microbiome collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.
MD Anderson and Genentech have entered into a mult-year clinical collaboration across rare-tumors.
Guardant Health and The University of Texas MD Adnerson Cancer Center entered a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment.
Hitachi and MD Anderson have entered into an agreement to collaborate on research for a unique randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck.
Idera Pharmaceuticals and The University of Texas MD Anderson Cancer Center enter into a strategic alliance to advance clinical development of intratumoral TLR9 agonist in combination with checkpoint inhibitors.
Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies.
Alliance to develop non-viral adoptive cellular cancer immunotherapies.
Combining advances made with Ionis’ antisense technology, which provides greatly enhanced potency enabling the inhibition of previously undruggable targets in tumor cells and immune cells of the tumor microenvironment, with MD Anderson’s expertise will allow Ionis and MD Anderson to develop novel therapeutic strategies to treat patients with a variety of cancers.
Iovance and MD Anderson have entered into a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers.
Jazz and MD Anderson will pursue research opportunities in areas of high unmet need with the goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
Strategic pre-clinical and clinical collaboration that will include development of KA2237 and KA2507.
MD Anderson announces that they have entered into a strategic collaboration with Merck to evaluate Merck’s anti-PD-1 therapy in combination with other treatments.
Nanobiotix and MD Anderson announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers, with the first trials to be launched in 2019.
The University of Texas MD Anderson Cancer Center and BridgeBio Pharma together launched Navire Pharma, a biopharmaceutical company aimed at developing novel small-molecule inhibitors of a tyrosine-protein phosphatase called SHP2 for genetically driven and treatment-resistant cancer.
Nektar Therapeutics and MD Anderson announce a research collaboration that includes a Phase 1/2 clinical study to evaluate NKTR-214.
Oncoceutics and MD Anderson team up on novel drug.
OncoResponse and MD Anderson collaborate to identify therapeutic antibodies against novel targets from immuno-oncology treated patients.
Polaris and MD Anderson Cancer Center signed a collaboration agreement to utilize MD Anderson's Immunotherapy Platform to design clinical studies and monitor biomarkers in immune functions associated with Polaris therapies. (April 2018)
MD Anderson and RaySearch Laboratories announced a strategic alliance with the aim of enhancing cancer radiation therapy through several initiatives, including more precisely targeting of tumors, and improving upon, and making more available, an existing radiation therapy called adaptive radiation therapy (ART), which is currently only used at highly specialized care centers.
An omics-based collaboration focused on brain metastasis.
MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an integrated software platform to streamline review of radiation oncology treatment plans.
Pre-clinical company focused on discovery and development of autophagy targeted therapeutics primarily for cancer treatment.